Physician profile
Andranik Howhannesian
NPI 1174591762
$6,148.76
in general payments reported to CMS, 2019-2025
34 companies · $482 in 2025
The $482 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $77.56 · 2021: $311 · 2022: $950 · 2023: $2,479 · 2024: $561 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Travel and Lodging: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.28 |
| Travel and Lodging | $1,110.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,700.40 | 2023-2024 | Axonics, Bulkamid |
| Neotract INC. | $1,120.41 | 2019 | |
| Teleflex LLC | $766.82 | 2021-2025 | Urolift |
| Astellas Pharma US INC | $495.63 | 2020-2024 | Myrbetriq, Xtandi |
| 180 Medical, INC. | $299.60 | 2019-2025 | |
| Abbvie INC. | $209.38 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $188.18 | 2023-2025 | Pylarify |
| Sumitomo Pharma America, INC. | $168.03 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $122.38 | 2019-2022 | |
| Antares Pharma, INC. | $101.40 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Myovant Sciences INC. | $99.46 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $93.59 | 2019-2023 | Xiaflex, Aveed |
| Telix Pharmaceuticals | $91.69 | 2023-2024 | Illuccix |
| Endo USA, INC. | $89.10 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $76.59 | 2024-2025 | Adstiladrin |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $73.68 | 2022 | |
| Olympus America INC. | $71.11 | 2021-2025 | Itind System |
| Tolmar, INC. | $62.78 | 2023-2024 | |
| Calyxo, INC. | $43.46 | 2025 | Cvac Aspiration System |
| Astrazeneca Pharmaceuticals Lp | $30.72 | 2023-2024 | Farxiga, Lynparza |
| Dendreon Pharmaceuticals LLC | $27.52 | 2023 | Provenge |
| Allergan, INC. | $24.12 | 2019-2022 | |
| Abbott Laboratories | $22.10 | 2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $20.88 | 2024 | Rivfloza |
| Urogen Pharma, INC. | $18.33 | 2025 | |
| Halozyme INC | $16.79 | 2023 | |
| Laborie Medical Technologies Corp. | $16.73 | 2025 | |
| Neurelis, INC. | $16.70 | 2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $15.25 | 2025 | Austedo Xr |
| Csl Behring | $14.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2022 | |
| Janssen Biotech, INC. | $13.51 | 2025 | Erleada |
| Tolmar Pharmaceuticals, INC. | $13.36 | 2020 | |
| Acorda Therapeutics, INC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andranik Howhannesian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.